116 related articles for article (PubMed ID: 9877245)
61. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
[TBL] [Abstract][Full Text] [Related]
62. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
63. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
64. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
65. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
[TBL] [Abstract][Full Text] [Related]
66. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
67. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes.
Pavlaki M; Debeli K; Triantaphyllidou IE; Klouras N; Giannopoulou E; Aletras AJ
J Biol Inorg Chem; 2009 Aug; 14(6):947-57. PubMed ID: 19390879
[TBL] [Abstract][Full Text] [Related]
68. The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model.
Ramos G; Loperena Y; Ortiz G; Reyes F; Szeto A; Vera J; Velez J; Morales J; Morrero D; Castillo L; Dharmawardhane S; Melendez E; Washington AV
Anticancer Res; 2014 Apr; 34(4):1609-15. PubMed ID: 24692689
[TBL] [Abstract][Full Text] [Related]
69. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Nicoletti MI; Lucchini V; Massazza G; Abbott BJ; D'Incalci M; Giavazzi R
Ann Oncol; 1993 Feb; 4(2):151-5. PubMed ID: 8095399
[TBL] [Abstract][Full Text] [Related]
70. Intracellular localization of titanium within xenografted sensitive human tumors after treatment with the antitumor agent titanocene dichloride.
Köpf-Maier P
J Struct Biol; 1990; 105(1-3):35-45. PubMed ID: 2100149
[TBL] [Abstract][Full Text] [Related]
71. Effect of glutamine on the immune function of paclitaxel intervention in ovarian cancer mice.
Wang L; Li Y; Wang J
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):193-197. PubMed ID: 32415947
[TBL] [Abstract][Full Text] [Related]
72. New Titanocene (IV) Dicarboxylates with Potential Cytotoxicity: Synthesis, Structure, Stability and Electrochemistry.
Guk DA; Gibadullina KR; Burlutskiy RO; Pavlov KG; Moiseeva AA; Tafeenko VA; Lyssenko KA; Gandalipov ER; Shtil AA; Beloglazkina EK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834751
[TBL] [Abstract][Full Text] [Related]
73. Subcellular distribution of titanium in the liver after treatment with the antitumor agent titanocene dichloride. A study using electron spectroscopic imaging.
Köpf-Maier P; Martin R
Virchows Arch B Cell Pathol Incl Mol Pathol; 1989; 57(4):213-22. PubMed ID: 2569781
[TBL] [Abstract][Full Text] [Related]
74. Synthesis and biological evaluation of achiral indole-substituted titanocene dichloride derivatives.
Deally A; Hackenberg F; Lally G; Tacke M
Int J Med Chem; 2012; 2012():905981. PubMed ID: 25954531
[TBL] [Abstract][Full Text] [Related]
75. Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model.
Yu HK; Lee HJ; Yun SJ; Lee SJ; Langley RR; Yoon Y; Yi LS; Bae DS; Kim JS; Kim SJ
Transl Oncol; 2014 Jun; 7(3):368-76. PubMed ID: 25180060
[TBL] [Abstract][Full Text] [Related]
76. Cytologic observations on the effects of metallocene dichlorides on human fibroblasts cultivated in vitro.
Köpf-Maier P; Hermann G
Virchows Arch B Cell Pathol Incl Mol Pathol; 1984; 47(2):107-22. PubMed ID: 6151291
[TBL] [Abstract][Full Text] [Related]
77. Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties.
Fernández-Gallardo J; Elie BT; Sulzmaier FJ; Sanaú M; Ramos JW; Contel M
Organometallics; 2014 Nov; 33(22):6669-6681. PubMed ID: 25435644
[TBL] [Abstract][Full Text] [Related]
78. Effect of Electrical Conductivity Through the Bulk Doping of the Product of Titanocene Dichloride and 2-Nitro-1,4-phenylenediamine.
Carraher CE; Battin AJ; Roner MR
J Funct Biomater; 2011 Mar; 2(1):18-30. PubMed ID: 24956060
[TBL] [Abstract][Full Text] [Related]
79. Morphological changes in the ovarian carcinoma cells of Wistar rats induced by chemotherapy with cisplatin and dioxadet.
Zhikhoreva AA; Belashov AV; Bespalov VG; Semenov AL; Semenova IV; Tochilnikov GV; Zhilinskaya NT; Vasyutinskii OS
Biomed Opt Express; 2018 Nov; 9(11):5817-5827. PubMed ID: 30460164
[TBL] [Abstract][Full Text] [Related]
80. On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy.
Gómez-Ruiz S; Maksimović-Ivanić D; Mijatović S; Kaluđerović GN
Bioinorg Chem Appl; 2012; 2012():140284. PubMed ID: 22844263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
